Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 148 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Turning the Life Sciences Vision into reality July 9, 2021 Adding Pembrolizumab to Chemotherapy with or without Bevacizumab Improves Overall Survival... January 9, 2024 Mathew Knowles, Father Of Beyoncé, Fought And Beat Breast Cancer November 5, 2019 A Novel Combination of Cabozantinib Plus Atezolizumab Demonstrates Encouraging Activity and... September 21, 2021 Load more HOT NEWS New on NCI’s Websites for December 2023 Selpercatinib Shows Durable Efficacy in RET Fusion–positive NSCLC Lessons from the green: How sports psychology helped a top golf... 3 Steps to Making the Right Decisions for You During Cancer:...
